Compare CKX & CNSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CKX | CNSY |
|---|---|---|
| Founded | 1930 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5M | 20.6M |
| IPO Year | 1996 | 2016 |
| Metric | CKX | CNSY |
|---|---|---|
| Price | $10.52 | $1.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 3.2K | ★ 85.1K |
| Earning Date | 11-09-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1125.00 | 87.61 |
| EPS | ★ 0.09 | N/A |
| Revenue | $838,543.00 | ★ $5,213,000.00 |
| Revenue This Year | N/A | $81.07 |
| Revenue Next Year | N/A | $102.79 |
| P/E Ratio | $118.78 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.66 | $1.86 |
| 52 Week High | $13.00 | $4.03 |
| Indicator | CKX | CNSY |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 28.54 |
| Support Level | $10.23 | N/A |
| Resistance Level | $11.71 | $3.28 |
| Average True Range (ATR) | 0.29 | 0.14 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 5.88 | 12.50 |
CKX Lands Inc is a Louisiana corporation organized to receive non-producing mineral royalties spun off by a southwest Louisiana bank. It operates in three segments: Oil and Gas, Surface, and Timber. The company owns land and mineral interests and collects income through its ownership of oil and gas royalties, surface leases for farming, the right of way, and other uses, and timber sales. The company's oil and gas royalties are paid by the operators who own the wells, and timber income is paid by the highest bidder for the timber. It has small royalty interests in approximately 20 different producing oil and gas fields. Maximum revenue for the company is generated from the Timber segment.
Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.